Patent focus on agents for tumour therapy: May - October 1999
Author: Ecker, G.
Source: Expert Opinion on Therapeutic Patents, Volume 9, Number 12, December 1999 , pp. 1627-1639(13)
Publisher: Informa Healthcare
This focus highlights the most interesting patent disclosures in the field of tumour therapy for the period of May - October 1999. Most of the patents discussed deal with inhibitors of signal transduction pathways, such as inhibitors of tyrosine kinases, serine/threonine kinases, cyclin dependent kinases and Ras-farnesyltransferases. Additionally, several compounds inhibiting adhesion and angiogenesis are discussed. Particularly interesting is the approach using a modified antibody directed enzyme prodrug therapy (ADEPT) concept with cyclodextrin complexes for detoxification and the concept of lipopeptides for formation of liposomes encapsulating irinotecan. Several new sequences for novel peptides useful in breast cancer therapy and diagnosis are also addressed.
Document Type: Miscellaneous
Affiliations: Institute of Pharmaceutical Chemistry, University of Vienna, Althanstrasse 14, A-1090 Wien, Austria. firstname.lastname@example.org
Publication date: December 1, 1999